Development and clinical application of contrast enhanced ultrasound Liver Imaging Reporting and Data System
10.3969/j.issn.1001-5256.2022.02.043
- VernacularTitle:超声造影肝脏影像报告和数据管理系统发展现状及临床应用进展
- Author:
Jianmin DING
1
,
2
;
Zhengyi QIN
1
,
2
;
Fang WANG
2
,
3
Author Information
1. Department of Ultrasound, Tianjin Third Central Hospital, Tianjin 300170, China
2. Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China
3. Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin 300170, China
- Publication Type:Reviews
- Keywords:
Carcinoma, Hepatocellular;
Ultrasonography;
Database Management Systems
- From:
Journal of Clinical Hepatology
2022;38(2):466-470
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence in China and the whole world, and early diagnosis and treatment are the key to improving the prognosis of patients. To facilitate the communication and cooperation between doctors of different centers and specialties, American College of Radiology issued the first edition of contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) in 2016 to standardize the technical terms, techniques, interpretation, reporting, and data collection for liver imaging and perform HCC risk stratification for different focal liver lesions. This article reviews the development and clinical application of CEUS LI-RADS and believes that the application of CEUS LI-RADS has a great potential value in the clinical management of focal liver lesions in the population at a high risk of HCC, and the applicable population and indications for CEUS LI-RADS will continue to expand in the near future, so as to provide better service to clinical practice.
